Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Galectin Therapeutic (GALT)
Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 109,410
  • Shares Outstanding, K 59,462
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,780 K
  • 60-Month Beta 1.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade GALT with:

Options Overview Details

View History
  • Implied Volatility 47.53% ( -6.84%)
  • Historical Volatility 79.35%
  • IV Percentile 14%
  • IV Rank 7.56%
  • IV High 530.21% on 12/21/22
  • IV Low 8.08% on 09/14/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 30
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 2,668
  • Open Int (30-Day) 2,609

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6336 +15.08%
on 08/28/23
2.0000 -6.00%
on 09/15/23
+0.2273 (+13.75%)
since 08/25/23
3-Month
1.2900 +45.74%
on 06/27/23
2.0000 -6.00%
on 09/15/23
+0.5600 (+42.42%)
since 06/26/23
52-Week
1.0200 +84.31%
on 12/28/22
2.4700 -23.89%
on 03/03/23
+0.3400 (+22.08%)
since 09/26/22

Most Recent Stories

More News
Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now

Galectin Therapeutics Inc. (GALT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement...

GALT : 1.8482 (+0.45%)
Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

NORCROSS, Ga., July 26, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin...

GALT : 1.8482 (+0.45%)
Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022

NORCROSS, Ga., June 21, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3,...

GALT : 1.8482 (+0.45%)
Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress

NORCROSS, Ga., May 23, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...

GALT : 1.8482 (+0.45%)
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

NORCROSS, Ga., May 16, 2022 (GLOBE NEWSWIRE) --  Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...

GALT : 1.8482 (+0.45%)
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y

Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.

CPRX : 12.25 (+0.99%)
GALT : 1.8482 (+0.45%)
ONTX : 0.7106 (-1.67%)
SLNO : 23.46 (+429.57%)
Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update

NORCROSS, Ga., March 31, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...

GALT : 1.8482 (+0.45%)
Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference

NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin...

GALT : 1.8482 (+0.45%)
Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein

NORCROSS, Ga., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin...

GALT : 1.8482 (+0.45%)
Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting

NAVIGATE clinical trial in NASH cirrhosis now underway in all countries originally selected; full enrollment expected by mid-2022 Dr. Chetan Bettegowda,...

GALT : 1.8482 (+0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring...

See More

Key Turning Points

3rd Resistance Point 2.0833
2nd Resistance Point 2.0067
1st Resistance Point 1.9233
Last Price 1.8482
1st Support Level 1.7633
2nd Support Level 1.6867
3rd Support Level 1.6033

See More

52-Week High 2.4700
Fibonacci 61.8% 1.9161
Last Price 1.8482
Fibonacci 50% 1.7450
Fibonacci 38.2% 1.5739
52-Week Low 1.0200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar